Kasr AL-Ainy's psoriasis unit protocol for the treatment of psoriasis, part II: biological therapies

被引：1

作者：

Rasheed, Hoda ^{[1
]}

AEl-Moaty, Hesham A. Z. ^{[1
]}

El-Komy, Mohamed H. M. ^{[1
]}

Mashaly, Heba ^{[1
,2
]}

Sayed, Khadiga S. ^{[1
]}

Hafez, Vanessa ^{[1
]}

El-Mesidy, Marwa S. ^{[1
]}

Said, Eman R. ^{[1
]}

Amer, Marwa A. ^{[1
]}

AlOrbani, Aya M. ^{[1
]}

Saadi, Dina G. ^{[1
]}

El-Kalioby, Mona ^{[1
]}

Eid, Reem O. ^{[1
]}

Azzazi, Yousra ^{[1
]}

机构：

[1] Cairo Univ, Fac Med, Dermatol Dept, Kasr Al Ainy Psoriasis Unit, Cairo, Egypt

[2] Cairo Univ, Fac Med, Cairo 11234, Egypt

来源：

JOURNAL OF EGYPTIAN WOMENS DERMATOLOGICAL SOCIETY | 2019年 / 16卷 / 02期

关键词：

biologic therapy; guidelines; psoriasis; TO-SEVERE PSORIASIS; LONGITUDINAL ASSESSMENT; NETWORK METAANALYSIS; HEPATITIS-B; MODERATE; USTEKINUMAB; SAFETY; RISK; EFFICACY; SECUKINUMAB;

D O I：

10.4103/JEWD.JEWD_13_19

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Psoriasis is a chronic multisystem inflammatory disease affecting primarily the skin and joints but also involves several comorbidities. The disease affects between 0.2 and 4% of the population worldwide. The Kasr Al-Ainy Psoriasis Unit developed a protocol of therapy for psoriasis. Part I discussed the topical and systemic therapies. This part discusses the biological therapy. Biological therapies for psoriasis are agents that can specifically target an immune mediator and block specific molecular steps important in the pathogenesis of psoriasis. Despite the cost, the use of biological therapies in psoriasis is sometimes necessary. However, the adequate choice of biologic in the proper indication is mandatory for cost-benefit balance for the patient. Physicians using biological therapies should be familiar with complications. The protocol offers regional physicians a practical algorithm for choice of biological therapies in psoriasis and a full workup before therapy and during follow-up. Authors highlight the safety and efficacy data of biologic therapies available in the Egyptian market, with special focus on particular situations (hepatitis, tuberculosis, and demyelinating disorders).

引用

页码：73 / 80

页数：8

共 33 条

[31] Treatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III randomized studies
Gottlieb, A. B.
Lacour, J. -P.
Korman, N.
Wilhelm, S.
Dutronc, Y.
Schacht, A.
Erickson, J.
Zhang, L.
Mallbris, L.
Gerdes, S.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 (04) : 679 - 685
[32] Severe Infliximab-Induced Alopecia and Scalp Psoriasis in a Woman with Crohn's Disease: Dramatic Improvement after Drug Discontinuation and Treatment with Adjuvant Systemic and Topical Therapies
Udkoff, Jeremy
Cohen, Philip R.
DERMATOLOGY AND THERAPY, 2016, 6 (04) : 689 - 695
[33] Severe Infliximab-Induced Alopecia and Scalp Psoriasis in a Woman with Crohn’s Disease: Dramatic Improvement after Drug Discontinuation and Treatment with Adjuvant Systemic and Topical Therapies
Jeremy Udkoff
Philip R. Cohen
Dermatology and Therapy, 2016, 6 : 689 - 695

← 1 2 3 4 →